- Eli Lilly (LLY) announced on Thursday that a late-stage trial for its next-generation weight loss candidate, retatrutide, met all primary and key secondary endpoints in obese or overweight adults with knee osteoarthritis but without diabetes.
- Based on topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to significant weight loss while improving pain and physical function over 68 weeks.
- Shares of Lilly (LLY) added ~3% in the premarket after the announcement, while its weight loss rival Novo Nordisk (NVO) traded flat.
This is a developing story. Check back for more updates.